Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.

Arteriosclerosis, thrombosis, and vascular biology - 1 Sept 2016

Roeseler Eberhard, Julius Ulrich, Heigl Franz, Spitthoever Ralf, Heutling Dennis, Breitenberger Paul, Leebmann Josef, Lehmacher Walter, Kamstrup Pia R, Nordestgaard Børge G, Maerz Winfried, Noureen Asma, Schmidt Konrad, Kronenberg Florian, Heibges Andreas, Klingel Reinhard

Abstract excerpt

OBJECTIVE: Lipoprotein(a)-hyperlipoproteinemia (Lp(a)-HLP) along with progressive cardiovascular disease has been approved as indication for regular lipoprotein apheresis (LA) in Germany since 2008. We aimed to study the long-term preventive effect of LA and to assess hypothetical clinical correlations of apolipoprotein(a) (apo(a)) by analyzing genotypes and phenotypes. APPROACH AND RESULTS: This prospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoprotein(a)
Share to Blood Component Removal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Germany

Share to Hyperlipoproteinemias

Share to Incidence

Share to Lipoprotein(a)

Share to Risk Assessment

Source

Identifiers

PMID: 27417585
DOI: 10.1161/ATVBAHA.116.307983

Genes

LPA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.PMID 27417585Read ↗

Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapiesSemantic proximity Read ↗

Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a).Semantic proximity Read ↗

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.Semantic proximity Read ↗

Lipoprotein(a): more interesting than ever after 50 years.Semantic proximity Read ↗

Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA)Semantic proximity Read ↗

Lipoprotein(a): the revenantSemantic proximity Read ↗

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?Semantic proximity Read ↗

Lipoprotein(a): Bridging the Gap Between Screening and Treatment—A Narrative ReviewSemantic proximity Read ↗

Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment PerspectivesSemantic proximity Read ↗

The Acute Effects of Lipoprotein Apheresis on Monocyte Subset Distribution and Transcriptome in Patients With and Without Elevated Lipoprotein(a)Semantic proximity Read ↗

Impact of Lipoprotein (a) on Residual Cardiovascular Risk after an Acute Coronary SyndromeSemantic proximity Read ↗

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.